|
Pain, pain, go away, don't come back another day should be Javelin Pharmaceuticals' mantra. The firm develops pain management drugs, usually by taking existing ones and making them more patient-friendly through improved formulations and modes of delivery. Javelin attempts to make products less invasive and faster acting in treating moderate to severe post-operative, post-trauma, burn, and cancer pain. Its three candidates, Dyloject, Ereska, and Rylomine (all in late-stage development), are based on already-approved prescription medications: diclofenac, ketamine, and morphine. Dyloject has been approved in the UK; Javelin is working to prepare its other products for regulatory approval in both the US and Europe.
|
| | | Contact Information | |
Address: |
125 Cambridge Park Dr.
Cambridge, MA 02140
| | Phone: | 617-349-4500 | | Fax: | 617-349-4505 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2008): | 1.10 M | | Employees (2008): | 35 | | Employee Growth (1 yr): | (-16.70%) |
|
|
Key People
| | • |
Chairman:
Douglas G. Watson
| | • |
CEO and Director:
Martin J. (Marty) Driscoll
| | • |
Vice Chairman, President, and Chief Medical Officer:
Daniel B. (Dan) Carr
|
|
|
